Although Transave's corporate and venture capital backers will own a minority, 46.7%, stake in the combined business with Insmed, its staff will take the senior jobs.
Transave, a US-based healthcare company to treat lung infections, has agreed effectively a reverse-takeover of Nasdaq-listed biopharmaceutical company Insmed.
Although Transave’s corporate and venture capital backers will own a minority, 46.7%, stake in the combined business, its staff will take the senior jobs.
Donald Hayden, Transave’s former chairman, will take the same role at the combined entity, while Timothy Whitten will be executive president and Renu Gupta will be chief medical officer.
From Insmed, Kevin Tully, will be chief…
